{"filing":{"accession_number":"0001213900-26-085235","cik":"0001946563","ticker":"SXTPW","company_name":"60 DEGREES PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-30","primary_document":"ea0300260-8k_60degrees.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026085235/ea0300260-8k_60degrees.htm"},"events":[{"id":23697,"run_id":21429,"accession_number":"0001213900-26-085235","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"60 Degrees Pharmaceuticals entered into a Securities Purchase Agreement on July 30, 2026, to issue approximately 574,713 shares of common stock (or pre-funded warrants), series A warrants, and series B warrants in a private placement for approximately $1.0 million in gross proceeds. The unregistered securities were issued under Section 4(a)(2) of the Securities Act and Regulation D, with a registration rights agreement requiring a resale registration statement, and proceeds are intended for working capital and general corporate purposes.","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24003,"accession_number":"0001213900-26-085235","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"60 Degrees Pharmaceuticals entered into a Securities Purchase Agreement on July 30, 2026, to issue 191,571 shares of common stock, 383,142 pre-funded warrants, and series A and B warrants in a private placement for approximately $1.0 million in gross proceeds. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act, raising capital through unregistered securities. The press release explicitly describes it as a private placement, and the company intends to use proceeds for working capital and R\u0026D—typical of a cash-strapped biotech raising capital. The inclusion of pre-funded warrants and multiple warrant tranches with low exercise prices ($0.001 for pre-funded, $1.49 for common warrants) further signals dilution. This is material to investors assessing ownership dilution and the company's capital position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:26:51.505900+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24004,"accession_number":"0001213900-26-085235","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a private placement of 574,713 shares of common stock (or pre-funded warrants), series A warrants, and series B warrants at $1.74 per share, generating approximately $1.0 million in gross proceeds. The securities are unregistered under Section 4(a)(2) of the Securities Act and Regulation D, with a registration rights agreement requiring a resale registration statement. This is a classic dilutive equity issuance by a small-cap pharmaceutical company raising capital, and the press release explicitly states the company intends to use proceeds for working capital and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:26:51.505900+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24006,"accession_number":"0001213900-26-085235","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The company announced a private placement of 574,713 shares of common stock (or pre-funded warrants), series A warrants, and series B warrants at $1.74 per share, generating approximately $1.0 million in gross proceeds. This is a classic unregistered equity issuance under Section 4(a)(2) and Regulation D, which dilutes existing shareholders. The filing explicitly notes the securities are unregistered and require a resale registration statement, and the company intends to use proceeds for working capital and general corporate purposes—typical of a PIPE or private placement by a small-cap pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:26:51.505900+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24003,"accession_number":"0001213900-26-085235","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"60 Degrees Pharmaceuticals entered into a Securities Purchase Agreement on July 30, 2026, to issue 191,571 shares of common stock, 383,142 pre-funded warrants, and series A and B warrants in a private placement for approximately $1.0 million in gross proceeds. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act, raising capital through unregistered securities. The press release explicitly describes it as a private placement, and the company intends to use proceeds for working capital and R\u0026D—typical of a cash-strapped biotech raising capital. The inclusion of pre-funded warrants and multiple warrant tranches with low exercise prices ($0.001 for pre-funded, $1.49 for common warrants) further signals dilution. This is material to investors assessing ownership dilution and the company's capital position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:26:51.505900+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-08-04"},{"id":24004,"accession_number":"0001213900-26-085235","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a private placement of 574,713 shares of common stock (or pre-funded warrants), series A warrants, and series B warrants at $1.74 per share, generating approximately $1.0 million in gross proceeds. The securities are unregistered under Section 4(a)(2) of the Securities Act and Regulation D, with a registration rights agreement requiring a resale registration statement. This is a classic dilutive equity issuance by a small-cap pharmaceutical company raising capital, and the press release explicitly states the company intends to use proceeds for working capital and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:26:51.505900+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-08-04"},{"id":24006,"accession_number":"0001213900-26-085235","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The company announced a private placement of 574,713 shares of common stock (or pre-funded warrants), series A warrants, and series B warrants at $1.74 per share, generating approximately $1.0 million in gross proceeds. This is a classic unregistered equity issuance under Section 4(a)(2) and Regulation D, which dilutes existing shareholders. The filing explicitly notes the securities are unregistered and require a resale registration statement, and the company intends to use proceeds for working capital and general corporate purposes—typical of a PIPE or private placement by a small-cap pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:26:51.505900+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-08-04"}]}